As predictive biomarkers, several studies investigating cytokines in ICI clinical trials have shown that a strong IFN-γ and/or TNF-α RNA signature was associated with improved response to ICIs in many cancer types, including RCC [107,108]. This evidence concerns the gene TNF and renal cell carcinoma.